Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nasus Pharma Ltd. ( (NSRX) ) has shared an update.
On March 16, 2026, Nasus Pharma reported positive top-line results from a 50-subject Phase 2 study showing its intranasal epinephrine candidate NS002 achieved significantly faster and higher early epinephrine absorption versus the intramuscular EpiPen autoinjector, with a median time to the critical 100 pg/mL plasma threshold of 1.69 minutes compared with 3.42 minutes and no serious safety events. The company, which also posted an updated investor presentation the same day, said NS002 maintained pharmacokinetic advantages in repeat dosing and in nasal challenge conditions simulating real-world allergic reactions, reinforcing its competitive positioning in anaphylaxis treatment as it targets initiation of a pivotal trial in the fourth quarter of 2026.
The Phase 2 data showed NS002 delivered roughly 50% higher epinephrine exposure in the first 10 minutes and a greater proportion of patients reaching therapeutic levels within 2.5 and 5 minutes than EpiPen, while achieving comparable peak plasma concentrations. These results, combined with a favorable tolerability profile, may enhance Nasus Pharma’s standing in the emergency allergy market by supporting a potential needle-free alternative that could expand treatment options and patient preference, with implications for future regulatory and commercial milestones if the planned pivotal program is successful.
The most recent analyst rating on (NSRX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Nasus Pharma Ltd. stock, see the NSRX Stock Forecast page.
More about Nasus Pharma Ltd.
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company developing intranasal powder products for acute medical conditions, with a focus on needle-free, easy-to-use alternatives that enable rapid drug delivery. Its lead candidate NS002 is an intranasal epinephrine powder being positioned as a substitute for traditional epinephrine autoinjectors in treating anaphylaxis, leveraging a proprietary powder-based intranasal technology for fast absorption.
Average Trading Volume: 6,361
Technical Sentiment Signal: Strong Sell
For an in-depth examination of NSRX stock, go to TipRanks’ Overview page.